COX-2 selective inhibitors--important lessons learned

Lancet. 2005 Feb 5-11;365(9458):449-51. doi: 10.1016/S0140-6736(05)17876-3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Celecoxib
  • Cyclooxygenase Inhibitors / adverse effects*
  • Drug Approval
  • Drug Labeling
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Lactones / adverse effects
  • Myocardial Infarction / chemically induced
  • Pyrazoles / adverse effects
  • Sulfonamides / adverse effects
  • Sulfones / adverse effects
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Lactones
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Celecoxib